通过调节HuR/SFPQ/TNF路径促进NSCLC的进展
Jiayue An1,2, Weimiao Sun1,2, Chenhui Ti1,2
1The Second Medical College of Binzhou Medical University, Yantai, Shandong, People's Republic of China.
在非小细胞肺癌 (NSCLC) 中,一种新型的循环RNA,circHMGCS1被上调. 它稳定了致癌的HuR蛋白,促进了SFPQmRNA的上调和NSCLC的进展,这表明它有可能作为诊断生物标志物.
科学领域:
- 癌症学
- 分子生物学
- 遗传学
背景情况:
- 非小细胞肺癌 (NSCLC) 是最常见的肺癌.
- 循环RNAs和RNA结合蛋白 (RBPs) 在癌症进展中起着至关重要的作用.
- 了解circRNA功能为NSCLC提供了潜在的治疗策略.
研究的目的:
- 识别和描述涉及NSCLC病变的新型circRNA.
- 阐明circRNAs影响NSCLC进展的分子机制.
- 评估circRNAs作为NSCLC的诊断和预后生物标志物的潜力.
主要方法:
- 用于新型circRNA识别的circRNA微阵列.
- 用于验证和表征的桑格测序和RNase R处理.
- 用于细胞增殖和迁移的功能分析的CCK-8和Transwell测定.
- 在机理学研究中进行RNA下拉,RNA免疫沉 (RIP),双露西法酶记者测定和actinomycin D治疗.
主要成果:
- 一种新的circRNA,circHMGCS1 (hsa_circ_0072387),被发现在NSCLC中具有上调作用.
- 通过抑制降解,circHMGCS1直接与HuR蛋白结合,使其稳定.
- 通过HuR调节SFPQmRNA的稳定性,从而促进NSCLC的进展.
- 通过抑制TNF信号,SFPQ可能会抑制细胞亡.
结论:
- circHMGCS1通过稳定致癌的HuR和上调SFPQ促进NSCLC的进展.
- circHMGCS1是NSCLC的潜在诊断和预后生物标志物.
- 针对circHMGCS1/HuR/SFPQ轴可能为NSCLC提供新的治疗途径.
更多相关视频
05:11Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
Published on: May 10, 2024
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
相关概念视频
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity
Regulation of Hematopoietic Stem Cells
